medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2000, Number 3

<< Back Next >>

Rev Mex Patol Clin Med Lab 2000; 47 (3)

Reactions to antirabic treatment in Ciego de Avila, Cuba. Review of 17 years

Suárez HM, Díaz VF, Sevilla PB, de los Reyes FJ, Álvarez GE

Language: Spanish
References: 13
Page: 162-167
PDF size: 78.89 Kb.


ABSTRACT

Reactions to antirabic treatment were evaluated in Ciego de Avila province from 1981 to 1997. Vaccinal reactions were considered for the patients that received serum or not; these presented positive sensibility tests and increased the clinical picture during the vaccination.
The sensibility tests defined to anti-rabic serum in patients to whom this biological agent was applied, were positive and the clinical picture did not increase during the immunization by vaccine. In the analized period the surveillance system detected 114 reactions of which 39 (34 %) were due to vaccine and 75 (66 %) due to heterologous antirabic serum.
The immunogens used were the antirabic vaccine Fuenzalid produced by Finlay Institute of the Republic of Cuba; the equine heterologous serum of Mesnikov Institue of Russia, and antirabic Gammaglobulin homologus of the Laboratories of Berna, Switzerland.
The local vaccinal reactions predominated over the systemic. Four neuroparalytic reactions were observed; one of the patients that presented it, died. Of the reactions to the serum, 52 % were local and 48 systemic. No reactions to the antirabic human Gammaglobulin were presented.


REFERENCES

  1. Scheneider MC, Santos Burgos C. Tratamiento contra la rabia humana: un poco de su historia, Rev Sal Pub Brasil, 1994 28(6) 454-462.

  2. Guarnera EA et al. Guía para el tratamiento de la rabia en el hombre, 2da. edición, OPS, 1996: 84.

  3. Svrcek S et al. Neuroparalytic Complications after Anti-Rabic Vaccine, 3ra. ed. Praha: Vet Med 1995; 40(2), 53-64.

  4. Zaneti CR et al. Reducid Schedule of Human Antirabies Immunization with Fuenzalida-Palacios Vaccine. Rev Inst Med Trop 995 31(1): 23-27.

  5. Reunión de Directores de Programas Nacionales para la Prevención y Eliminación de la Rabia en América Latina, Informe Final, V. 27, OPS 1995; 40: 25-27.

  6. Souza Mateos L, Haroldo NC, Valdetaro HH. Efeito de una Dose Reforce Na Vacinacao Antirrábica. Foha Med Brasil 1996; 92(3) 143-148.

  7. Dávila R. Vacuna antirrábica de (CRL). Tratamiento humano post exposición. En el Ecuador, Boletín Oficina Sanitaria Panamericana 1997; 105(2) 151-158.

  8. Wilde H, Chamchey P et al. Neuroparalytic Accidents of Vaccination Antirrabic. Arch Neurol 42, 1997; 13(6): 593-596.

  9. Alvarez E, Ruiz A. Situación de la rabia en América Latina de 1988-1994. Bol Oficina Sanit 1995; 119(5) 451-456.

  10. Brilla JC, Quenzer RV. Infections Disease In Emegency Medicine 1ª. Ed., N York: Little Brown and Company 1995: 98-99.

  11. Chirigello S. Estudio epidemiológico retrospectivo sobre atención a personas expuestas al virus rábico, Ministerio de Salud y Asistencia Social, El Salvador; 1995.

  12. Gómez Barrios F. Vacunas antirrábicas humanas. Arch Venez Pediatric 1996; 54: 58-62.

  13. Chutivongse SWH, Benjavongkulchai M. Postexpresure Rabies Vaccination During Pregnancy: Effect on 202 Women and Their Infants. Clin Infect Dis 1995; 20(4): 818-20.




2020     |     www.medigraphic.com